Q-omics provides the consensus-scored CYP4F30P profile across patient tissues and cancer cell-line models. CYP4F30P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CYP4F30P is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, CYP4F30P RNA expression shows 10,373 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, BRCA, and THYM as cancer lineages where CYP4F30P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F30P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F30P survival associations across molecular data types. CYP4F30P RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F30P RNA expression–survival associations across cancer types. High CYP4F30P expression shows unfavorable associations in STAD, DLBC, KIRP, COAD and LUAD, but favorable associations in PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CYP4F30P RNA expression.
This table summarizes CYP4F30P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4F30P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F30P shows lower tumor expression in LUAD and higher tumor expression in BRCA, HNSC, LUSC, PRAD and BLCA. The BRCA box plot shows higher CYP4F30P RNA expression in tumor versus normal tissue (log2 FC = +0.193, t-test p = .012).
This table shows molecular features associated with CYP4F30P in patient tissues and cancer cell lines. In patient samples, CYP4F30P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
